Investors
Saniona Icon blue

Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world.

The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical development. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION).

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Upcoming Events
Financial Calendar
26 August 2021 at 8:00 AM CEST August 26, 2021 at 8:00 AM CEST
Interim Report Q2
18 November 2021 at 8:00 AM CET November 18, 2021 at 8:00 AM CET
Interim Report Q3
24 February 2022 at 8:00 AM CET February 24, 2022 at 8:00 AM CET
Year-End Report 2021
If you have any questions regarding Saniona's investor communication, feel free to contact us at any time.
trista morrison
Trista Morrison, Chief Communications Officer Email: investor@saniona.com